Cabozantinib with nivolumab for untreated advanced renal cell carcinoma

  • Technology appraisal guidance
  • TA964
  • Published: 
Download (PDF)

2 Recommendations for research

2.1

The committee recommended that future renal cell carcinoma trials should be sufficiently powered to analyse differences in treatment effect by risk group (see section 1.9).

2.2

The committee highlighted areas in the analysis and evidence that could benefit from future research:

  • understanding long-term health-related quality of life in the real world (see section 1.27)

  • survival benefit of immunotherapies in the real world (see section 1.23)

  • understanding how clear and non-clear cell RCC responds to different treatments (see section 1.10)

  • the impact of adjuvant treatment on the effectiveness of advanced treatment (see section 1.11).